Navigation Links
NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study
Date:11/4/2008

0.011) in favor of naproxcinod.

Michele Garufi, Chairman and CEO of NicOx, commented: "These excellent results are an important addition to the consistent data we are accumulating on naproxcinod's potentially non-detrimental blood pressure profile and its clear differentiation from naproxen. We are confident that naproxcinod's potential will be confirmed by the further clinical results expected in the coming months."

The three doses of naproxcinod showed good general safety and tolerability. In the naproxcinod arm 32 patients (54.2%) experienced one or more adverse events, compared to 38 patients (64.4%) in the naproxen arm. There were no serious adverse events in the naproxcinod arm.

Additional note on study design: The 111 study was a 12-week pharmacodynamic ABPM trial (with 9 weeks of active treatment), with a double-blind, parallel group design, in which 118 OA patients with controlled hypertension were enrolled at 30 clinical sites in the United States. Eligible patients were 40 years and older and had been suffering from osteoarthritis for at least three months, with at least one hip or knee involved. In addition to OA, all patients were diagnosed with controlled essential hypertension (i.e. SBP <140 mmHg and DBP <90 mmHg) and were treated with stable doses of up to two different classes of antihypertensive agents. Patients with uncontrolled hypertension were excluded.

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) a product-driven biopharmaceutical company dedicated to the development and future commercialization of investigational drugs for unmet medical needs. NicOx is applying its proprietary nitric oxide-donating technology to develop an internal portfolio of New Chemical Entities (NCEs) in the therapeutic areas of inflammatory and cardio-metabolic disease.

Resources are focused on the development of naproxcinod, a proprietary NCE and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

1082

GOOD

Page: 1 2 3 4

Related medicine technology :

1. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
2. NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension
3. NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients
4. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
5. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
6. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
7. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
8. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
9. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
10. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
11. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014  TNI BioTech, Inc. ... company focused on the development, marketing and distribution ... filed definitive proxy materials with the Securities and ... Meeting of Shareholders to be held on Thursday, ... Time. The record date for determining those shareholders ...
(Date:7/28/2014)... ANGELES , SINGAPORE, and TOKYO , ... announced that it has appointed Roger Crystal , ... most recently served in the Global Business Development Product ... "Roger,s experience in developing business strategy and ... valuable as we continue to partner with biotechnology and ...
(Date:7/28/2014)... 28, 2014 PDL BioPharma, Inc. (PDL) (NASDAQ: ... its second quarter 2014 financial results for the period ended ... close. PDL,s management will host a conference call and webcast ... financial results.  A slide presentation relating to the call will ... Conference Call Details To access the live ...
Breaking Medicine Technology:TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 3ImaginAb Appoints Roger Crystal, MD as Vice President of Business Development 2PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014 2
... SYDNEY, Australia, June 16 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,(ASX: PXS; ... Limited to,manage and provide eligible patients worldwide with ... The program will allow patients who are unable ... are considered by their physician,to be suffering from ...
... Claims Cover Anti-Viral Applications of Novel Targeted Agents Under ... Company,s Anti-Phospholipid Technology Platform -, - Anti-Viral ... Presented at American Association of Immunologists Annual Meeting ... (Nasdaq: PPHM ), a clinical stage biopharmaceutical,company developing ...
Cached Medicine Technology:Pharmaxis Establishes Named Patient Program for Bronchitol 2Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio 2Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio 3Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio 4
(Date:7/28/2014)... A lush green lawn offers the perfect ... However, the summer heat, lack of rain, foot traffic, and ... and unhealthy. The Grounds Guys recommends these suggestions for nurturing ... once a week and set the height on the lawn ... grass roots from heat and allows roots to retain water ...
(Date:7/28/2014)... 28, 2014 An estimated 68,000 women ... metastatic breast and prostate cancers – an aggressive form ... spread to other parts of the body, such as ... Drexel University College of Medicine have developed ... inhibits metastatic progression by blocking tumor cells from β€œre-seeding.” ...
(Date:7/28/2014)... 28, 2014 Ticket Down is ... tickets in Dallas, TX at the Cotton Bowl. The ... the USA and it is an eight team tourney. ... world including teams from La Liga, Serie A, English Premier ... battle it out on the pitch include: Manchester United, ...
(Date:7/28/2014)... 2014 Ticket Down is a ... in Miami, FL at the Sun Life Stadium in early ... between Argentina and Brazil has is one that has continues ... rivalries are forming on a consistent basis. The rivalry ... height in the recent 2014 World Cup. To the ...
(Date:7/28/2014)... Steven Reinberg HealthDay ... People who have dementia and heart rhythm irregularities are more ... research has found. In fact, the study of more ... to 80 percent more likely to get a pacemaker than ... from this study is why folks with dementia are so ...
Breaking Medicine News(10 mins):Health News:Nurturing Lawns in the Summer Heat: The Grounds Guys® Offers Tips on Caring for Lawns This Summer 2Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 2Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 3Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 3Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 2Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 3Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 3
... Deficit Hyperactivity Disorder (ADHD) is a prevailing issue in ... every year. A new study reveals that Pycnogenol, (pic-noj-en-all), ... French maritime pine tree, reduces ADHD in children. The ... and dopamine, resulting in a decrease of ADHD. ...
... NSERC Idea to Innovations grant and an Ontario Early ... and Nanosystems Laboratory ( http://amnl.mie.utoronto.ca ) at the University ... technology for automated microinjection of zebrafish embryos. , ... microrobotic system is capable of immobilizing a large number ...
... (Sept. 12, 2007) For the first time in ... ocean corals in its annual report of wildlife going ... by Conservation International (CI) and implemented jointly with the ... Charles Darwin Research Station and other regional institutions to ...
... helps teens make better food choices as adults, study finds ... dinner with their families on a regular basis are also ... a new study shows. , These teens also go on ... , Reporting in the Journal of the American Dietetic ...
... Medical,Technologies, Inc. today reported to its board of ... to include England, Canada, New,Zealand and Australia. ... began to come in as a result of ... the ReBuilder System(R). Through,word of mouth and the ...
... may be the last taboo,in our society, a subject that ... to fear -- to be avoided no matter what the ... "Triumph" is the result of daily writing over the ... about Darlyne,s,impending death and Philip,s loss. They have written this ...
Cached Medicine News:Health News:New study: Pine bark extract reduces ADHD symptoms in children 2Health News:Corals added to IUCN Red List of Threatened Species for first time 2Health News:Corals added to IUCN Red List of Threatened Species for first time 3Health News:ReBuilder Medical Technologies, Inc. Reports International Sales Expansion 2Health News:ReBuilder Medical Technologies, Inc. Reports International Sales Expansion 3Health News:ReBuilder Medical Technologies, Inc. Reports International Sales Expansion 4Health News:'Triumph' -- Traveling Towards Death: Preparing for a New Life 2
... , Combined Advanced Technologies, The ... technologically advanced combination of high pressure ... Proprietary coextrusion process yields a remarkably ... conventional high pressure balloon materials., Non-Compliant ...
Used retrograde to dilate the ureter and establish a conduit for a flexible ureteroscope. Supplied sterile in peel-open packages. Intended for one-time use....
... Diameter; 5.4 Fr Straight Channel; 33 or ... MRO-7 Integral Operating Ureteroscopes offer a small ... easy access to the ureter for diagnosis ... Fr) is ideal for large operating instruments, ...
... self-dilating, semi-rigid autoclavable operating ureteroscope featuring distortion-free ... for an enhanced, clear image. The universal ... diopters. The direction of view is 5 ... straight access operating channel is ideal for ...
Medicine Products: